Jason Amartey
YOU?
Author Swipe
View article: The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease
The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease Open
A novel potential treatment for peripheral arterial disease (PAD) is described. Inhibition of SRPK1, or knockout in monocytes, induces angiogenesis by preventing splicing to antiangiogenic VEGF (VEGF-A 165 b) in patients and animal models.…
View article: The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease
The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease Open
Introduction In peripheral arterial disease (PAD) anti-angiogenic VEGF-A 165 b isoform overexpression in monocytes contributes to impaired collateralisation. Serine-arginine protein-kinase-1 (SRPK1) regulates VEGF splicing. To determine wh…
View article: Nigella sativa Extract and Thymoquinone Regulate Inflammatory Cytokine and TET-2 Expression in Endothelial Cells
Nigella sativa Extract and Thymoquinone Regulate Inflammatory Cytokine and TET-2 Expression in Endothelial Cells Open
Numerous natural compounds including Nigella sativa (N. sativa) demonstrate anti-infammatory and anti-diabetic antiangiogenic properties. Lipopolysaccharide (LPS) mediated inflammation is regarded as an important contributor to the inflamm…